180 related articles for article (PubMed ID: 16870764)
1. Effects of caspofungin against Candida guilliermondii and Candida parapsilosis.
Barchiesi F; Spreghini E; Tomassetti S; Della Vittoria A; Arzeni D; Manso E; Scalise G
Antimicrob Agents Chemother; 2006 Aug; 50(8):2719-27. PubMed ID: 16870764
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Etest method for determining caspofungin (MK-0991) susceptibilities of 726 clinical isolates of Candida species.
Pfaller MA; Messer SA; Mills K; Bolmström A; Jones RN
J Clin Microbiol; 2001 Dec; 39(12):4387-9. PubMed ID: 11724849
[TBL] [Abstract][Full Text] [Related]
3. Anti-metabolic activity of caspofungin against Candida albicans and Candida parapsilosis biofilms.
Cocuaud C; Rodier MH; Daniault G; Imbert C
J Antimicrob Chemother; 2005 Sep; 56(3):507-12. PubMed ID: 16040622
[TBL] [Abstract][Full Text] [Related]
4. Species-specific and drug-specific differences in susceptibility of Candida biofilms to echinocandins: characterization of less common bloodstream isolates.
Simitsopoulou M; Peshkova P; Tasina E; Katragkou A; Kyrpitzi D; Velegraki A; Walsh TJ; Roilides E
Antimicrob Agents Chemother; 2013 Jun; 57(6):2562-70. PubMed ID: 23529739
[TBL] [Abstract][Full Text] [Related]
5. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates.
Park S; Kelly R; Kahn JN; Robles J; Hsu MJ; Register E; Li W; Vyas V; Fan H; Abruzzo G; Flattery A; Gill C; Chrebet G; Parent SA; Kurtz M; Teppler H; Douglas CM; Perlin DS
Antimicrob Agents Chemother; 2005 Aug; 49(8):3264-73. PubMed ID: 16048935
[TBL] [Abstract][Full Text] [Related]
6. Sequential therapy with caspofungin and fluconazole for Candida albicans infection.
Barchiesi F; Spreghini E; Baldassarri I; Marigliano A; Arzeni D; Giannini D; Scalise G
Antimicrob Agents Chemother; 2004 Oct; 48(10):4056-8. PubMed ID: 15388480
[TBL] [Abstract][Full Text] [Related]
7. National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin.
Takakura S; Fujihara N; Saito T; Kudo T; Iinuma Y; Ichiyama S
J Antimicrob Chemother; 2004 Feb; 53(2):283-9. PubMed ID: 14688039
[TBL] [Abstract][Full Text] [Related]
8. Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome.
Kartsonis N; Killar J; Mixson L; Hoe CM; Sable C; Bartizal K; Motyl M
Antimicrob Agents Chemother; 2005 Sep; 49(9):3616-23. PubMed ID: 16127030
[TBL] [Abstract][Full Text] [Related]
9. Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis.
Hernandez S; López-Ribot JL; Najvar LK; McCarthy DI; Bocanegra R; Graybill JR
Antimicrob Agents Chemother; 2004 Apr; 48(4):1382-3. PubMed ID: 15047549
[TBL] [Abstract][Full Text] [Related]
10. The efficiency of the benzothiazole APB, the echinocandin micafungin, and amphotericin B in fluconazole-resistant Candida albicans and Candida dubliniensis.
Melkusová S; Bujdáková H; Volleková A; Myoken Y; Mikami Y
Pharmazie; 2004 Jul; 59(7):573-4. PubMed ID: 15296100
[TBL] [Abstract][Full Text] [Related]
11. [Study of in vitro activity of caspofungin on non-Candida albicans yeast strains determined by two methods: M27-A2 and EUCAST].
Romero M; Cantón E; Pemán J; Gobernado M
Rev Esp Quimioter; 2004 Sep; 17(3):257-62. PubMed ID: 15619655
[TBL] [Abstract][Full Text] [Related]
12. Caspofungin therapy of neonates with invasive candidiasis.
Odio CM; Araya R; Pinto LE; Castro CE; Vasquez S; Alfaro B; Sàenz A; Herrera ML; Walsh TJ
Pediatr Infect Dis J; 2004 Dec; 23(12):1093-7. PubMed ID: 15626944
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Etest method for determining posaconazole MICs for 314 clinical isolates of Candida species.
Pfaller MA; Messer SA; Mills K; Bolmström A; Jones RN
J Clin Microbiol; 2001 Nov; 39(11):3952-4. PubMed ID: 11682513
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species.
Vazquez JA; Lynch M; Boikov D; Sobel JD
Antimicrob Agents Chemother; 1997 Jul; 41(7):1612-4. PubMed ID: 9210698
[TBL] [Abstract][Full Text] [Related]
15. Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations.
Stevens DA; Espiritu M; Parmar R
Antimicrob Agents Chemother; 2004 Sep; 48(9):3407-11. PubMed ID: 15328104
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of the new echinocandin antifungal, MK-0991, against common and uncommon clinical isolates of Candida species.
Barchiesi F; Schimizzi AM; Fothergill AW; Scalise G; Rinaldi MG
Eur J Clin Microbiol Infect Dis; 1999 Apr; 18(4):302-4. PubMed ID: 10385023
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis.
Abruzzo GK; Flattery AM; Gill CJ; Kong L; Smith JG; Pikounis VB; Balkovec JM; Bouffard AF; Dropinski JF; Rosen H; Kropp H; Bartizal K
Antimicrob Agents Chemother; 1997 Nov; 41(11):2333-8. PubMed ID: 9371329
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice.
Abruzzo GK; Gill CJ; Flattery AM; Kong L; Leighton C; Smith JG; Pikounis VB; Bartizal K; Rosen H
Antimicrob Agents Chemother; 2000 Sep; 44(9):2310-8. PubMed ID: 10952573
[TBL] [Abstract][Full Text] [Related]
19. Differential effects of the combination of caspofungin and terbinafine against Candida albicans, Candida dubliniensis and Candida kefyr.
Gil-Lamaignere C; Müller FM
Int J Antimicrob Agents; 2004 May; 23(5):520-3. PubMed ID: 15120736
[TBL] [Abstract][Full Text] [Related]
20. In vitro antifungal activities and in vivo efficacies of 1,3-beta-D-glucan synthesis inhibitors L-671,329, L-646,991, tetrahydroechinocandin B, and L-687,781, a papulacandin.
Bartizal K; Abruzzo G; Trainor C; Krupa D; Nollstadt K; Schmatz D; Schwartz R; Hammond M; Balkovec J; Vanmiddlesworth F
Antimicrob Agents Chemother; 1992 Aug; 36(8):1648-57. PubMed ID: 1416847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
